OS Therapies (OSTX) Payables (2023 - 2026)
OS Therapies' (OSTX) quarterly Payables came in at $17.0 million in Q1 2026, up 751.25% YoY from $2.0 million in Q1 2025, and up 44.56% on a QoQ basis from $11.7 million in Q4 2025.
OS Therapies (OSTX) Payables (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Payables data on file, last reported at $17.0 million in Q1 2026.
- Quarterly Payables rose 751.25% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 751.25% YoY) and the FY2025 annual result came in at $11.7 million, up 475.65% from the prior year.
- Payables rose to $17.0 million in Q1 2026, from $11.7 million in the prior quarter.
- In the past five years, Payables ranged from a high of $17.0 million in Q1 2026 to a low of $31250.0 in Q1 2023.
- A 4-year average of $4.4 million and a median of $2.1 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2024 — Payables surged 10377.18% — and 2025, when it plunged 63.9%.
- Tracing OSTX's Payables over 4 years: stood at $5.1 million in 2023, then plunged by 59.94% to $2.0 million in 2024, then soared by 475.65% to $11.7 million in 2025, then soared by 44.56% to $17.0 million in 2026.
- The last three Payables figures came in at $17.0 million (Q1 2026), $11.7 million (Q4 2025), and $775000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 35.57 Mn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | 20.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.95 Mn |
| Dec 31, 2025 | 11.73 Mn |
| Sep 30, 2025 | 775,000.00 |
| Jun 30, 2025 | 3.08 Mn |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | 5.09 Mn |
| Mar 31, 2023 | 31,250.00 |